Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Rizzo

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Expert Opinion on Therapeutic Targets|August 13, 2008
Could starvation minimize chemotherapy-induced toxicities?Antonio Russo, Sergio Rizzo
Oncotarget|January 6, 2017
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapyGemma Bruera, Antonio Russo, Antonio Galvano, et al.
Critical Reviews in Oncology/Hematology|May 12, 2009
Male breast cancerLaura Ottini, Domenico Palli, Sergio Rizzo, et al.
Therapeutic Advances in Drug Safety|August 22, 2025
Safety profiles of the new target therapies-pemigatinib, futibatinib, and ivosidenib-for the treatment of cholangiocarcinoma: a systematic reviewGiulia Matranga, Anna Carollo, Miriam Alaimo, et al.
Critical Reviews in Oncology/Hematology|July 29, 2008
Hereditary ovarian cancerAntonio Russo, Valentina Calò, Loredana Bruno, et al.
Current Cancer Drug Targets|January 22, 2010
Bortezomib: a new pro-apoptotic agent in cancer treatmentAntonio Russo, Giuseppe Bronte, Fabio Fulfaro, et al.
Breast Cancer (Dove Medical Press)|December 25, 2013
HER2-positive male breast cancer: an updateLaura Ottini, Carlo Capalbo, Piera Rizzolo, et al.
Critical Reviews in Oncology/Hematology|March 23, 2017
EGFR inhibition in NSCLC: New findings…. and opened questions?Francesco Passiglia, Angela Listì, Marta Castiglia, et al.
International Journal of Cancer|October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumabFrancesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Expert Opinion on Emerging Drugs|January 28, 2010
Anti-endothelin drugs in solid tumorsAntonio Russo, Giuseppe Bronte, Sergio Rizzo, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Expert Opinion on Therapeutic Targets|August 13, 2008
Could starvation minimize chemotherapy-induced toxicities?Antonio Russo, Sergio Rizzo
Oncotarget|January 6, 2017
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapyGemma Bruera, Antonio Russo, Antonio Galvano, et al.
Critical Reviews in Oncology/Hematology|May 12, 2009
Male breast cancerLaura Ottini, Domenico Palli, Sergio Rizzo, et al.
Therapeutic Advances in Drug Safety|August 22, 2025
Safety profiles of the new target therapies-pemigatinib, futibatinib, and ivosidenib-for the treatment of cholangiocarcinoma: a systematic reviewGiulia Matranga, Anna Carollo, Miriam Alaimo, et al.
Critical Reviews in Oncology/Hematology|July 29, 2008
Hereditary ovarian cancerAntonio Russo, Valentina Calò, Loredana Bruno, et al.
Current Cancer Drug Targets|January 22, 2010
Bortezomib: a new pro-apoptotic agent in cancer treatmentAntonio Russo, Giuseppe Bronte, Fabio Fulfaro, et al.
Breast Cancer (Dove Medical Press)|December 25, 2013
HER2-positive male breast cancer: an updateLaura Ottini, Carlo Capalbo, Piera Rizzolo, et al.
Critical Reviews in Oncology/Hematology|March 23, 2017
EGFR inhibition in NSCLC: New findings…. and opened questions?Francesco Passiglia, Angela Listì, Marta Castiglia, et al.
International Journal of Cancer|October 29, 2017
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumabFrancesco Passiglia, Antonio Galvano, Sergio Rizzo, et al.
Expert Opinion on Emerging Drugs|January 28, 2010
Anti-endothelin drugs in solid tumorsAntonio Russo, Giuseppe Bronte, Sergio Rizzo, et al.
Pageof 7